Clinical Trial Update: 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the use of the radiotracer 68-Gallium DOTATATE PET/MRI for diagnosing and managing somatostatin receptor–positive CNS tumors…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Tumors
• Esthesioneuroblastoma
• Hemangioblastoma
• Medulloblastoma
• Meningioma
• Paraganglioma
• Pituitary Adenoma

Drugs mentioned

• 68-Gallium DOTATATE (68Ga-DOTATATE) (DOTATATE labeled with Gallium-68)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: CNS Tumors, Meningioma | Phase 4 | Status: RECRUITING